- Home
- YMM vs MDGL Comparison
YMM vs MDGL Comparison
Compare YMM & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMM | MDGL |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 12.0B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | YMM | MDGL |
|---|---|---|
| Price | $8.20 | $542.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $12.00 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 6.8M | 331.2K |
| Earning Date | 05-20-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.07% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | N/A | $58.28 |
| Revenue Next Year | $12.22 | $46.80 |
| P/E Ratio | $18.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.04 | $265.00 |
| 52 Week High | $14.07 | $615.00 |
Technical Indicators
Market Signals| Indicator | YMM | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 36.04 | 73.47 |
| Support Level | N/A | $535.33 |
| Resistance Level | $9.47 | $572.20 |
| Average True Range (ATR) | 0.24 | 26.64 |
| MACD | 0.02 | 11.53 |
| Stochastic Oscillator | 14.22 | 79.21 |
Price Performance
Historical ComparisonAbout YMM Full Truck Alliance Co. Ltd. (each representing 20)
Full Truck Alliance Co Ltd, through its subsidiaries, provides comprehensive services for shippers and truckers through its mobile and website platforms. Its principal operations are in the People's Republic of China. The group derives its revenues principally from shippers and trucker's use of its platforms in connection with freight matching services and value-added services.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.